{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:31:05Z","timestamp":1793662265639,"version":"4.5.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health","award":["DK007199"],"award-info":[{"award-number":["DK007199"]}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K08AG055670"],"award-info":[{"award-number":["K08AG055670"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of the cardiovascular, kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among patients with diabetic kidney disease (DKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched electronic databases for major randomized placebo-controlled clinical trials published up to September 30, 2021 and reporting on cardiovascular and kidney outcomes of SGLT2i in patients with DKD. DKD was defined as chronic kidney disease in individuals with type 2 diabetes. Random-effects meta-analysis models were used to estimate pooled hazard ratios (HR) and 95% confidence intervals (CI) for clinical outcomes including major adverse cardiovascular events (MACE: myocardial infarction [MI], stroke, and cardiovascular death), kidney composite outcomes (a combination of worsening kidney function, end-stage kidney disease, or death from renal or cardiovascular causes), hospitalizations for heart failure (HHF), deaths and safety events (mycotic infections, diabetic ketoacidosis [DKA], volume depletion, amputations, fractures, urinary tract infections [UTI], acute kidney injury [AKI], and hyperkalemia).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 26,106 participants with DKD from 8 large-scale trials were included (median age: 65.2\u00a0years, 29.7\u201341.8% women, 53.2\u201393.2% White, median follow-up: 2.5\u00a0years). SGLT2i were associated with reduced risks of MACE (HR 0.83, 95% CI 0.75\u20130.93), kidney composite outcomes (HR 0.66, 95% CI 0.58\u20130.75), HHF (HR 0.62, 95% CI 0.55\u20130.71), cardiovascular death (HR 0.84, 95% CI 0.74\u20130.96), MI (HR\u00a00.78, 95% CI 0.67\u20130.92), stroke (HR 0.76, 95% CI 0.59\u20130.97), and all-cause death (HR 0.86, 95% CI 0.77\u20130.96), with no significant heterogeneity detected. Similar results were observed among participants with reduced estimated glomerular filtration rate (eGFR:\u2009&lt;\u200960\u00a0mL\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      ). The relative risks (95% CI) for adverse events were 3.89 (1.42\u201310.62) and 2.50 (1.32\u20134.72) for mycotic infections in men and women respectively, 3.54 (0.82\u201315.39) for DKA, and 1.29 (1.13\u20131.48) for volume depletion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among adults with DKD, SGLT2i were associated with reduced risks of MACE, kidney outcomes, HHF, and death. With a few exceptions of more clear safety signals, we found overall limited data on the associations between SGLT2i and safety outcomes. More research is needed on the safety profile of SGLT2i in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-022-01476-x","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T08:06:02Z","timestamp":1648022762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":138,"title":["Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Arnaud D.","family":"Kaze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"1476_CR1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/jama.2015.10029","volume":"314","author":"A Menke","year":"2015","unstructured":"Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988\u20132012. JAMA. 2015;314:1021\u20139.","journal-title":"JAMA"},{"key":"1476_CR2","unstructured":"Centers for Disease Control and Prevention, Department of Health and Human Services. National Diabetes statistics report, 2020 estimates of diabetes and its burden in the United States [Internet]. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html. Accessed 7 Oct 2021."},{"key":"1476_CR3","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.2337\/diacare.24.11.1936","volume":"24","author":"JP Boyle","year":"2001","unstructured":"Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care. 2001;24:1936\u201340.","journal-title":"Diabetes Care"},{"key":"1476_CR4","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1476_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1476_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1476_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1476_CR8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1476_CR9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1476_CR10","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425\u201335.","journal-title":"N Engl J Med"},{"key":"1476_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1476_CR12","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0529","author":"ST Harris","year":"2021","unstructured":"Harris ST, Patorno E, Zhuo M, Kim SC, Paik JM. Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study. Diabetes Care. 2021. https:\/\/doi.org\/10.2337\/dc21-0529.","journal-title":"Diabetes Care"},{"key":"1476_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1476_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"1476_CR15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","volume":"52","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke. 2021;52:1545\u201356.","journal-title":"Stroke"},{"key":"1476_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129\u201339.","journal-title":"N Engl J Med"},{"key":"1476_CR17","unstructured":"Kaze AD, Zhuo M, Paik JM. Association of SGLT2 inhibitors with clinical outcomes in patients with type 2 diabetes and diabetic kidney disease: a systematic review and meta-analysis. PROSPERO 2021; CRD42021282869.https:\/\/www.crd.york.ac.uk\/prospero\/#recordDetails. Accessed 14 Nov 2021."},{"key":"1476_CR18","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"1476_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119\u201329.","journal-title":"Circulation"},{"key":"1476_CR20","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","volume":"138","author":"BL Neuen","year":"2018","unstructured":"Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018;138:1537\u201350.","journal-title":"Circulation"},{"key":"1476_CR21","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1681\/ASN.2019010064","volume":"30","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J Am Soc Nephrol. 2019;30:2229\u201342.","journal-title":"J Am Soc Nephrol"},{"key":"1476_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","volume":"140","author":"KW Mahaffey","year":"2019","unstructured":"Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019;140:739\u201350.","journal-title":"Circulation"},{"key":"1476_CR23","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1681\/ASN.2019111168","volume":"31","author":"MJ Jardine","year":"2020","unstructured":"Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020;31:1128\u201339.","journal-title":"J Am Soc Nephrol"},{"key":"1476_CR24","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","volume":"42","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Sj\u00f6str\u00f6m CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021;42:1216\u201327.","journal-title":"Eur Heart J"},{"key":"1476_CR25","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","volume":"142","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020;142:2205\u201315.","journal-title":"Circulation"},{"key":"1476_CR26","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1476_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/sim.4780080202","volume":"8","author":"JA Berlin","year":"1989","unstructured":"Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141\u201351.","journal-title":"Stat Med"},{"key":"1476_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101\u201329.","journal-title":"Biometrics"},{"key":"1476_CR29","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"1476_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"1476_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117\u201328.","journal-title":"N Engl J Med"},{"key":"1476_CR32","doi-asserted-by":"publisher","first-page":"e27362","DOI":"10.1097\/MD.0000000000027362","volume":"100","author":"L-M Zhao","year":"2021","unstructured":"Zhao L-M, Huang J-N, Qiu M, Ding L-L, Zhan Z-L, Ning J. Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: a meta-analysis of cardiovascular outcome trials. Medicine (Baltimore). 2021;100:e27362.","journal-title":"Medicine (Baltimore)"},{"key":"1476_CR33","doi-asserted-by":"publisher","first-page":"e014908","DOI":"10.1161\/JAHA.119.014908","volume":"9","author":"C Arnott","year":"2020","unstructured":"Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9:e014908.","journal-title":"J Am Heart Assoc"},{"key":"1476_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148\u201358.","journal-title":"JAMA Cardiol"},{"key":"1476_CR35","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.2215\/CJN.02690320","volume":"15","author":"J Li","year":"2020","unstructured":"Li J, Albajrami O, Zhuo M, Hawley CE, Paik JM. Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease. Clin J Am Soc Nephrol. 2020;15:1678\u201388.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1476_CR36","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1016\/j.jacc.2019.02.071","volume":"73","author":"N Bansal","year":"2019","unstructured":"Bansal N, Zelnick L, Bhat Z, Dobre M, He J, Lash J, et al. Burden and outcomes of heart failure hospitalizations in adults with chronic kidney disease. J Am Coll Cardiol. 2019;73:2691\u2013700.","journal-title":"J Am Coll Cardiol"},{"key":"1476_CR37","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1007\/s00125-019-4926-x","volume":"62","author":"T Ohkuma","year":"2019","unstructured":"Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62:1550\u201360.","journal-title":"Diabetologia"},{"key":"1476_CR38","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1681\/ASN.2014030253","volume":"26","author":"M Sud","year":"2015","unstructured":"Sud M, Tangri N, Pintilie M, Levey AS, Naimark DMJ. ESRD and death after heart failure in CKD. J Am Soc Nephrol. 2015;26:715\u201322.","journal-title":"J Am Soc Nephrol"},{"key":"1476_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0984-0","author":"SR Yurista","year":"2020","unstructured":"Yurista SR, Sillj\u00e9 HHW, Rienstra M, de Boer RA, Westenbrink BD. Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? Cardiovasc Diabetol. 2020. https:\/\/doi.org\/10.1186\/s12933-019-0984-0.","journal-title":"Cardiovasc Diabetol"},{"key":"1476_CR40","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation. 2020;141:1227\u201334.","journal-title":"Circulation"},{"key":"1476_CR41","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","volume":"20","author":"H-L Li","year":"2021","unstructured":"Li H-L, Lip GYH, Feng Q, Fei Y, Tse Y-K, Wu M-Z, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021;20:100.","journal-title":"Cardiovasc Diabetol"},{"key":"1476_CR42","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART cardiolink-6 randomized clinical trial. Circulation. 2019;140:1693\u2013702.","journal-title":"Circulation"},{"key":"1476_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-020-0990-2","volume":"19","author":"S-C Shao","year":"2020","unstructured":"Shao S-C, Chang K-C, Lin S-J, Chien R-N, Hung M-J, Chan Y-Y, et al. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients. Cardiovasc Diabetol. 2020;19:17.","journal-title":"Cardiovasc Diabetol"},{"key":"1476_CR44","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.09.015","author":"M Zhuo","year":"2021","unstructured":"Zhuo M, Paik JM, Wexler DJ, Bonventre JV, Kim SC, Patorno E. SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes. Am J kidney Dis Off J Natl Kidney Found. 2021. https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.015.","journal-title":"Am J kidney Dis Off J Natl Kidney Found."},{"key":"1476_CR45","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2337\/dc17-1011","volume":"40","author":"GN Nadkarni","year":"2017","unstructured":"Nadkarni GN, Ferrandino R, Chang A, Surapaneni A, Chauhan K, Poojary P, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care. 2017;40:1479\u201385.","journal-title":"Diabetes Care"},{"key":"1476_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2215\/CJN.11220720","volume":"16","author":"M Zhao","year":"2020","unstructured":"Zhao M, Sun S, Huang Z, Wang T, Tang H. Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury. Clin J Am Soc Nephrol. 2020;16:70\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1476_CR47","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/j.ajkd.2020.03.019","volume":"76","author":"C Rampersad","year":"2020","unstructured":"Rampersad C, Kraut E, Whitlock RH, Komenda P, Woo V, Rigatto C, et al. Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study. Am J kidney Dis Off J Natl Kidney Found. 2020;76:471-479.e1.","journal-title":"Am J kidney Dis Off J Natl Kidney Found"},{"key":"1476_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160478","author":"Y-K Chang","year":"2016","unstructured":"Chang Y-K, Choi H, Jeong JY, Na K-R, Lee KW, Lim BJ, et al. Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0160478.","journal-title":"PLoS ONE"},{"key":"1476_CR49","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/dom.13301","volume":"20","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018;20:1988\u201393.","journal-title":"Diabetes Obes Metab"},{"key":"1476_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7066.1157","author":"RE Ferner","year":"1996","unstructured":"Ferner RE. Newly licensed drugs. BMJ. 1996. https:\/\/doi.org\/10.1136\/bmj.313.7066.1157.","journal-title":"BMJ"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01476-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01476-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01476-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T05:08:12Z","timestamp":1661922492000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01476-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01476-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No potential conflicts of interest relevant to this article were reported. EP is principal investigator of an investigator-initiated grant to the Brigham and Women\u2019s Hospital from Boehringer Ingelheim, not related to the topic of the submitted work. SK has received research grants to the Brigham and Women\u2019s Hospital from Pfizer, AbbVie, Roche and Bristol-Myers Squibb for studies not related to the topic of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}